Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Will Cover Hepatitis C Screening For Baby Boomers, High Risk Populations

This article was originally published in The Gray Sheet

Executive Summary

CMS finalized a decision to cover screening for the Hepatitis C virus under Medicare for all adults born between 1945 and 1965, and all “high risk” adults.

You may also be interested in...



News Briefs: Approvals For Abbott’s MitraClip, Allergan’s Juvéderm; Diagnostics News

FDA approved Abbott’s MitraClip to treat mitral regurgitation and Allergan’s Juvéderm Voluma XC facial filler to temporary correct volume-loss. Hepatitis C testing will be mandatory in New York. More news.

Federal Task Force Recommends One-Time HCV Screening For All Baby Boomers

The U.S. Preventative Services Task Force recommends a one-time hepatitis C screening for all baby boomers, an expansion of the group’s previous recommendations.

Finance Watch: Karuna, Cerevel And Others Benefit From Improving Biotech Sentiment

Good news in the biopharma industry and the US economy gave public drug developers the boost they needed to raise cash, including Karuna’s $750m offering. Private company financings slowed during the second week of August, but Prellis and Vector BioPharma raised venture capital.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT033064

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel